Which Helicobacter pylori-positive dyspeptics are likely to respond symptomatically to empirical H. pylori eradication?
Related Experiment Video
Updated: Sep 12, 2026

Quantitative Polymerase Chain Reaction (qPCR)-Based Rapid Diagnosis of Helicobacter pylori Infection and Antibiotic Resistance
Published on: July 28, 2023
M A Asante1, M A Mendall, T C Northfield
1Department of Gastroenterology, Endocrinology and Metabolism, St George's Hospital Medical School, London, UK.
Objective:
To identify which Helicobacter pylori-positive dyspeptic patients have an increased likelihood of having peptic ulcer and may thus be more likely to benefit from empirical H. pylori eradication therapy.
Methods:
622 out of 740 consecutive dyspeptic subjects (median age 45 years, range 14-91, 51% male) attending for rapid access endoscopy were eligible for the study. Demographic data and endoscopic findings were recorded. H. pylori status was determined by urease and histology.
Results:
In all age groups, peptic ulcers were commoner in males than females [44% (85/195) vs 23% (32/139), P < 0.001] and in smokers than non-smokers [47% (46/97) vs 32% (50/159), P < 0.05]. Males, heavy smokers and those with a family history of peptic ulcer had increased adjusted odds of having a peptic ulcer (2.59, 1.96 and 1.90, respectively). Corresponding odds ratios for those aged under 45 were 2.59, 0.94 and 2.52. In H. pylori-positive dyspepsia, being a male who either smoked heavily or had a family history of peptic ulcer gave a sensitivity and positive predictive value for peptic ulcer of 86 and 45% for all age groups and 85 and 49% for those aged under 45.
Conclusion:
Male H. pylori dyspeptics who smoke >10 cigarettes per day and/or have a family history of peptic ulcer are likely to have peptic ulcer and are thus likely to benefit from empirical eradication therapy.
More Related Videos
05:23Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
04:56Detection of Helicobacter pylori Infection and Antibiotic Resistance via Stool Quantitative Polymerase Chain Reaction Analysis
Published on: May 16, 2025
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer
Gastritis II: Pathophysiology
Peptic Ulcer Disease II: Pathophysiology